WISE S.p.A., a medical device company focused on implantable electrodes for neuromonitoring, neuromodulation and brain-computer interface (BCI) applications, has completed an oversubscribed Series D financing round worth €30 million.

The funding round included participation from ENEA Tech and Biomedical, an Italian foundation that supports innovation and technology transfer in the biomedical sector. The organisation joins WISE as a strategic investor.

The final closing follows the first phase of the financing completed in June 2024. That round included a venture debt facility from the European Investment Bank (EIB), supported by InvestEU, as well as equity investments from Wallaby S.p.A. and existing investors New Frontier S.r.l., Eureka Venture SGR and Indaco Ventures SGR.

Most of the funding will be used to support the development and clinical adoption of the Heron® lead, WISE’s main product for spinal cord stimulation (SCS). The Heron® lead is designed to provide targeted and directional stimulation through a minimally invasive percutaneous implantation procedure.

According to the company, the device combines the precision of surgical paddle leads with the lower procedural demands of cylindrical leads. This approach is intended to improve energy efficiency, expand anatomical coverage, enhance neural signal sensing and reduce lead migration in patients receiving treatment for chronic pain.

The proceeds will also support regulatory certification activities and a first-in-human study for the Heron® lead. In addition, the company plans to expand commercial operations for its broader electrode portfolio in key markets.

WISE’s technology platform is based on its proprietary Supersonic Technology, which enables the production of implantable electrodes and BCI systems using stretchable electronic circuits integrated into ultra-thin elastomeric materials. The technology is designed to offer greater flexibility, tissue conformity and adhesion compared with conventional rigid electrodes.

The company believes these characteristics can improve safety, treatment effectiveness and the accuracy of neural signal recording and stimulation.

Part of the funding will also support the wider commercial rollout of the WISE Cortical Strip (WCS®), a soft and stretchable electrode used for intraoperative neurophysiological monitoring during brain tumour and epilepsy surgery.

The WCS® has received CE marking under the Medical Device Regulation (MDR), making it the first cortical strip for intraoperative neurophysiological monitoring to achieve this certification. The product has also received FDA clearance and is commercially available in Europe, the United States and Australia.

 

Source: businesswire.com

Report Abuse